A Study of MORAb-003 in Patients With Solid Tumor

Phase 1

Completed

• Conditions: Neoplasms; Solid Tumor
• Interventions: Drug: MORAb-003

• Registration Number: NCT01049061
• Lead Sponsor: Eisai Co., Ltd.

Brief Summary

MORAb-003 is intravenously administered to Japanese patients with folate receptor-alpha expressing solid tumor once a week for 4 weeks as 1 cycle in order to investigate dose-limiting toxicity and estimate maximum tolerated dose.

Detailed Description

Not available

Study Timeline

• Study Start: 2010-01
• Study First Submitted: 2010-01-13
• Study First Submitted QC: 2010-01-13
• Study First Posted: 2010-01-14
• Primary Completion: 2013-01
• Study Completion: 2013-02
• Status Verified: 2014-02
• Last Update Submitted: 2020-06-08
• Last Update Posted: 2020-06-11

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 16

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
MORAb-003	MORAb-003	-

Primary Outcome Measures

Name	Time	Method
To investigate dose-limiting toxicity and estimate maximum tolerated dose.	7 weeks